Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Post by Marky1on Sep 07, 2020 5:05pm
473 Views
Post# 31518336

Dr. John Wallace

Dr. John Wallace

This man is the guru of anti-inflammatoires GI science..He has published more than 400 peer reviewed papers...He has written more than 100 chapters on the topic of H2S technology....He is in the top  0.5% of the worlds top scientists receiving citations of his works ( that's the biography at the end of a study ) over 28,000 citations..He has given more than 500 lectures all over the world..
Lets think of all the work that he has done on ATB 346 since he invented it back around 2004.. An entire lifes hardwork all coming to a head! A Nobel Prize should be coming his way..
2021 will be the year for ATE ! 

The majority of his wealth, along with his buddy, Dan Legault rests on his ownership of ATE stock..They both deserve a hearty thank you from every shareholder..
At the end of the road we'll all reap the rewards of their hard work
GLTA

<< Previous
Bullboard Posts
Next >>